Statistical Rarity
Bayesian rare-event estimation; 0 of 8,655 patients, exact 95% bound below 1 in 2,889
Jeffreys Median Ultra-rare
2.63e-5
Posterior median under Jeffreys Beta(0.5, 0.5) prior
Patients for 50%
25,965
From the zero count alone (Jeffreys); ignores gene frequencies
Gene Level (fitted)
about 1 in 25,000
All five genes mutated, fitted pairwise maximum-entropy (Ising) model; the exact variants have no model value
Combined Search Zero
0 matches
8,655 GENIE patients, all five genes on panel
Jeffreys Posterior Estimation
With 0 observed quintuples in 8,655 myeloid patients, the Jeffreys
non-informative prior Beta(0.5, 0.5) yields a posterior Beta(0.5, 8,655.5).
The posterior median (2.63e-5) represents the best point estimate of the true
population frequency. The 95% credible interval spans
5.67e-8 to 2.90e-4, providing bounds on the
plausible frequency range.
| Statistic | Value | Interpretation |
|---|---|---|
| Posterior median | 2.63e-5 | Best point estimate of true frequency |
| Posterior mean | 5.78e-5 | Mean of Beta(0.5, 8,655.5) |
| 95% CI lower | 5.67e-8 | Lower 2.5th percentile |
| 95% CI upper | 2.90e-4 | Upper 97.5th percentile |
| One-sided 95% upper | 2.22e-4 | Conservative upper bound |
Source: bayesian_rarity_results.json.
Jeffreys prior: non-informative conjugate prior for binomial data.
Rule of Three (Frequentist)
The Rule of Three (Hanley and Lippman-Hand, 1983) provides a quick frequentist upper
bound: with 0 events in n trials, the 95% upper confidence limit is approximately 3/n.
For 8,655 patients, this gives an upper bound of 3.47e-4.
The Clopper-Pearson exact interval (3.46e-4) and
Poisson exact 99% bound (5.32e-4) provide alternative
frequentist estimates, all consistent with the Bayesian credible interval.
Patients are the unit (several samples from one patient are merged), so the
Clopper-Pearson bound is the figure used elsewhere on this portal: below 1 in 2,889.
| Method | Upper Bound | Confidence Level |
|---|---|---|
| Rule of Three | 3.47e-4 | 95% |
| Clopper-Pearson exact | 3.46e-4 | 95% |
| Poisson exact | 5.32e-4 | 99% |
Source: bayesian_rarity_results.json.
Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? JAMA (1983).
Gene-Level vs Variant-Level Rarity
The five genes (DNMT3A, IDH2, SETBP1, PTPN11, EZH2) are individually common in
myeloid malignancies. At the gene level, with frequencies from the REVOLVER input
(7,956 patients, all carrying at least one target-gene mutation, so enriched),
the expected co-occurrence count is
8.99e-3 (0.0034 with the
frequencies of the 18,625 panel-eligible samples), placing this
combination at the 77.8th percentile among all 278,256 possible five-gene
combinations from 34 myeloid genes. A fitted pairwise maximum-entropy (Ising) model puts
mutations in all five genes at about 1 in 25,000 myeloid patients (1 in 13,000 to 1 in 65,000).
The exact five-variant combination has no estimable population frequency. Zero in 8,655 patients bounds it below 1 in 2,889 (95%, exact binomial). An earlier "variant specificity" multiplier was withdrawn on 3 November 2026: it gave EZH2 V662A, which has 0 carriers, an arbitrary 1/N value.
The exact five-variant combination has no estimable population frequency. Zero in 8,655 patients bounds it below 1 in 2,889 (95%, exact binomial). An earlier "variant specificity" multiplier was withdrawn on 3 November 2026: it gave EZH2 V662A, which has 0 carriers, an arbitrary 1/N value.
Gene-Level Expected
8.99e-3
REVOLVER-input frequencies (enriched); 77.8th percentile among 278,256 combinations
Quintuple Bound
< 1 in 2,889
Exact 95% bound from 0 of 8,655 patients; no point estimate
Source: bayesian_rarity_results.json.
Extreme Value Theory: Coles S. Statistical Modeling of Extreme Values. Springer (2001).
Combined Database Search
Zero quintuple matches in GENIE v19.0: 18,625 panel-eligible samples from
8,655 myeloid patients, sequenced on 27 different panels at 11 GENIE
member centers. HARMONY Alliance holds 12,041 AML patients from European
institutions on a 41-gene panel (Eurofins-Biomnis) that covers all five genes, but its
public dashboard could not be queried for co-occurrence (at capacity in March 2026,
unreachable on 2 November 2026) and has no SETBP1 filter, so it is not counted.
| Database | Patients | Panel | All 5 Genes Covered | Quintuple Matches |
|---|---|---|---|---|
| GENIE v19.0 | 8,655 (18,625 samples) | Variable (27 panels) | Yes | 0 |
| HARMONY Alliance | 12,041 | 41-gene panel | Yes | Not queried |
| Counted total | 8,655 | 0 |
Gene-level frequencies in HARMONY (AML-only): DNMT3A 25.2%,
IDH2 12.7%,
PTPN11 7.5%,
EZH2 6% (literature estimate),
SETBP1 2% (literature estimate; the
dashboard has no SETBP1 filter). Under independence, the expected number of gene-level
quintuples in HARMONY alone is
0.035.
Source: harmony_results.json.
AACR Project GENIE Consortium (2017). HARMONY Alliance (harmony-alliance.eu).
Posterior Predictive: Patients Needed
Using the Jeffreys posterior, the probability of observing at least one quintuple match
in a future cohort of M patients is computed via the posterior predictive distribution.
25,965 patients are needed for a 50% chance of finding one match.
3,453,444 patients are needed for 95% confidence. These figures use only the
observation 0 of 8,655 patients and ignore the gene frequencies. At gene level, a fitted
pairwise maximum-entropy (Ising) model puts mutations in all five genes at about 1 in 25,000
patients; for the exact five variants no model value is defensible, because EZH2 V662A
has 0 carriers.
| Future Cohort Size | P(at least 1 match) |
|---|---|
| 1,000 | 5.3% |
| 5,000 | 20.4% |
| 10,000 | 31.9% |
| 50,000 | 61.6% |
| 100,000 | 71.8% |
| 500,000 | 87.0% |
| 1,000,000 | 90.7% |
50% Detection
25,965 patients
Future cohort needed for 50% chance of 1 match
95% Detection
3,453,444 patients
Future cohort needed for 95% chance of 1 match
Source: bayesian_rarity_results.json.
Posterior predictive under Jeffreys conjugate Beta prior.
Extreme Value Theory
All 278,256 possible five-gene combinations from
the 34 target myeloid genes were enumerated and their expected counts computed under
independence. A Generalized Extreme Value (GEV) distribution was fitted to the
log-transformed expected counts. The patient quintuple ranks 216,373 out
of 278,256 at the gene level (77.8th
percentile), confirming that these five genes are individually common enough in myeloid
malignancies that their gene-level co-occurrence is unremarkable. The exact variant
combination has no estimable frequency beyond the exact bound (below 1 in 2,889).
| EVT Metric | Value | Interpretation |
|---|---|---|
| Gene-level percentile | 77.8th | Genes common, combination not extreme |
| Gene-level expected count | 8.99e-3 | Expected quintuples at gene level (REVOLVER-input frequencies, enriched) |
| Fitted Ising, all five genes | about 1 in 25,000 | Pairwise maximum-entropy model, patient level (1 in 13,000 to 1 in 65,000) |
| GEV shape parameter | 0.2278 | scipy c > 0, i.e. ξ < 0: bounded (Weibull-type) tail, not heavy-tailed |
The fitted GEV shape is c = 0.23 in scipy's sign convention,
which is ξ = -0.23 in the usual one: a bounded (Weibull-type)
tail, not a heavy tail, so the rarest gene combinations do not stretch out without limit.
The patient quintuple sits in the body of this distribution at the gene level.
Source: bayesian_rarity_results.json.
Coles S. Statistical Modeling of Extreme Values. Springer (2001).
Babur et al. Genome Biol (2015). Canisius et al. Genome Biol (2016).
References
- AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017). DOI
- Coles S. An Introduction to Statistical Modeling of Extreme Values. Springer Series in Statistics (2001). DOI
- Babur O, Gonen M, Aksoy BA, et al. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol (2015). DOI
- Canisius S, Martens JW, Wessels LF. A novel independence test for somatic alterations in cancer. Genome Biol (2016). DOI
- Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA (1983). PubMed